{"id":"W2596694419","doi":"10.1200/jco.2012.30.15_suppl.1036","title":"A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne; University of Toronto; Kingston General Hospital; Interior Health; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Baker Hughes (Canada); London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Rash; Clinical endpoint; Progressive disease; Adverse effect; Interim analysis; Nausea; Gastroenterology; Phases of clinical research; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006035612,0.0002096057,0.002590166,0.0003182901,0.00004546162,0.000004850036,0.0002039309,0.0002391453,0.0008961982],"category_scores_gemma":[0.001771025,0.0001476853,0.0005218998,0.0003978706,0.000149751,0.0001878764,0.000063184,0.00128344,0.000003711796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002638363,"about_ca_system_score_gemma":0.00189178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001596,"about_ca_topic_score_gemma":0.0004736536,"domain_scores_codex":[0.9940959,0.0009333949,0.003787081,0.0002087425,0.000574667,0.0004001734],"domain_scores_gemma":[0.9942509,0.001513912,0.003084535,0.0002292733,0.000425188,0.0004961953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3894441,0.0733861,0.01027304,0.00004048636,0.0007378658,0.0001583883,0.002642685,0.000002234837,0.0001529603,0.0001369538,0.001600128,0.521425],"study_design_scores_gemma":[0.6684235,0.2827759,0.03323271,0.000333227,0.0009896799,0.0002880433,0.002272948,0.00006604545,0.0001128734,0.0009022135,0.01040852,0.000194275],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904547,0.0009789249,0.00006180862,0.001879251,0.005088531,0.001206072,0.00003244242,0.000005833121,0.0002923748],"genre_scores_gemma":[0.9949161,0.000992703,0.000733964,0.0006155366,0.002559277,0.00004143185,0.000001817109,0.00002438329,0.0001148189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5212307,"threshold_uncertainty_score":0.9812742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2071610312700796,"score_gpt":0.5449791943742308,"score_spread":0.3378181631041512,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}